Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 2Ovarian Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Head and Neck Neoplasms 1HER2-low Breast Cancer 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oxaliplatin 64pembrolizumab 48Fluorouracil 44Capecitabine 38Nivolumab 33Leucovorin 32Paclitaxel 28Trastuzumab 19Docetaxel 18Cisplatin 18S 1 (combination) 16Bevacizumab 15Ramucirumab 13Irinotecan 13Drug Therapy 13tislelizumab 12Cyclophosphamide 12fludarabine 10Carboplatin 10Radiotherapy 9Magnetic Resonance Spectroscopy 9trastuzumab deruxtecan 8sintilimab 8Specimen Handling 8Biopsy 8atezolizumab 7Surgical Procedures, Operative 7Gemcitabine 7zolbetuximab 6durvalumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × RC48 antibody × 1 year × Clear all
NCT06157892 2026-05-05

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Seagen Inc.

Phase 2 Recruiting
172 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡